genotype of primary tumor for tailored therapy.Ren, Chuanli; Han, Chongxu; Fu, Deyuan; Wang, Daxin; Chen, Hui; Chen, Yong; Shen, Ming.Int J Cancer; 138(7): 1586-600, 2016 Apr 1.137.Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.Mardekian, Stacey K; Bombonati, Alessandro; Palazzo, Juan P.Hum Pathol; 49: 114-23, 2016 Mar.138.Biological markers of invasive breast cancer.Matsumoto, Akiko; Jinno, Hiromitsu; Ando, Tomofumi; Fujii, Taku; Nakamura, Tetsuya; Saito, Junichi; Takahashi, Maiko;Hayashida, Tetsu; Kitagawa, Yuko.Jpn J Clin Oncol; 46(2): 99-105, 2016 Feb.139.Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.Garcia-Teijido, Paula; Cabal, Maria Luque; Fernandez, Ignacio Pelaez; Perez, Yolanda Fernandez.Clin Med Insights Oncol; 10(Suppl 1): 31-9, 2016.140.Prognostic significance of CD24 and CD44 in breast cancer: a meta-analysis.Wang, Zhu; Wang, Qianqian; Wang, Qi; Wang, Yanping; Chen, Jie.Int J Biol Markers; : 0, 2016 Jul 27.141.Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Pruneri, Giancarlo; Gray, Kathryn P; Vingiani, Andrea; Viale, Giuseppe; Curigliano, Giuseppe; Criscitiello, Carmen; Lang, Istvan; Ruhstaller, Thomas; Gianni, Lorenzo; Goldhirsch, Aron; Kammler, Roswitha; Price, Karen N; Cancello, Giuseppe;Munzone, Elisabetta; Gelber, Richard D; Regan, Meredith M; Colleoni, Marco.Breast Cancer Res Treat; 158(2): 323-31, 2016 Jul.142.Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.Iglesia, Michael D; Parker, Joel S; Hoadley, Katherine A; Serody, Jonathan S; Perou, Charles M; Vincent, Benjamin G.J Natl Cancer Inst; 108(11)2016 Nov.143.Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.Miller, Lance D; Chou, Jeff A; Black, Michael A; Print, Cristin; Chifman, Julia; Alistar, Angela; Putti, Thomas; Zhou, Xiaobo;Bedognetti, Davide; Hendrickx, Wouter; Pullikuth, Ashok; Rennhack, Jonathan; Andrechek, Eran R; Demaria, Sandra;Wang, Ena; Marincola, Francesco M.Cancer Immunol Res; 4(7): 600-10, 2016 Jul.144.Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.King, Tari A; Lyman, Jaclyn P; Gonen, Mithat; Voci, Amy; De Brot, Marina; Boafo, Camilla; Sing, Amy Pratt; Hwang, E Shelley; Alvarado, Michael D; Liu, Minetta C; Boughey, Judy C; McGuire, Kandace P; Van Poznak, Catherine H; Jacobs, Lisa K; Meszoely, Ingrid M; Krontiras, Helen; Babiera, Gildy V; Norton, Larry; Morrow, Monica; Hudis, Clifford A.J Clin Oncol; 34(20): 2359-65, 2016 Jul 10.145.Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.Yamashita, Hiroko; Ogiya, Akiko; Shien, Tadahiko; Horimoto, Yoshiya; Masuda, Norikazu; Inao, Touko; Osako, Tomofumi;Takahashi, Masato; Endo, Yumi; Hosoda, Mitsuchika; Ishida, Naoko; Horii, Rie; Yamazaki, Kieko; Miyoshi, Yuichiro;Yasojima, Hiroyuki; Tomioka, Nobumoto.Breast Cancer; 23(6): 830-843, 2016 Nov.146.The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis.Lu, Yan-Jun; Wang, Peng; Wang, Xiong; Peng, Jing; Zhu, Yao-Wu; Shen, Na.Oncotarget; 7(24): 37361-37369, 2016 Jun 14.147.Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer.Sawada, Takeshi; Araki, Jungo; Yamashita, Toshinari; Masubuchi, Manami; Chiyoda, Tsuneko; Yunokawa, Mayu; Hoshi, Kumiko; Tao, Shoichi; Yamamura, Shohei; Yatsushiro, Shouki; Abe, Kaori; Kataoka, Masatoshi; Shimoyama, Tatsu;Maeda, Yoshiharu; Kuroi, Katsumasa; Tamura, Kenji; Sawazumi, Tsuneo; Minami, Hironobu; Suda, Yoshihiko; Koizumi, Fumiaki.EBioMedicine; 11: 173-182, 2016 Sep.148.Multi-gene classifiers for prediction of recurrence in breast cancer patients.Naoi, Yasuto; Noguchi, Shinzaburo.Breast Cancer; 23(1): 12-8, 2016 Jan.149.High